

ENDOCARE INC  
Form 8-K  
August 17, 2004

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 17, 2004

**ENDOCARE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-27212**

(Commission File Number)

**33-0618093**

(IRS Employer Identification No.)

**201 Technology Drive, Irvine, California 92618**

(Address of principal executive offices, including zip code)

**(949) 450-5400**

(Registrant's telephone number, including area code)

---

**TABLE OF CONTENTS**

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9. REGULATION FD DISCLOSURE

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits.

99.1 Slides to be used in August 17, 2004 presentation.

**ITEM 9. REGULATION FD DISCLOSURE**

On August 17, 2004, Craig T. Davenport, our Chairman and Chief Executive Officer, and William J. Nydam, our President and Chief Operating Officer, will make a presentation at the New Ideas conference sponsored by CJS Securities, Inc., using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1.

This Current Report on Form 8-K, the information contained herein, and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission. The information contained herein and in the accompanying exhibit shall not be incorporated by reference to any of our filings, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The filing of this Current Report on Form 8-K is not an admission as to the materiality of any information in this report or the attached exhibit.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

**ENDOCARE, INC.**

Date: August 17, 2004

By: /s/ Michael R. Rodriguez  
Michael R. Rodriguez  
Chief Financial Officer and  
Senior Vice President, Finance